Moreover, recent therapeutic approaches in p53-deficient tumors focus on synthetic lethality, exemplified by the use of Poly(ADP-ribose)-Polymerase (PARP) inhibitors in cancers with additional somatic BRCA1/2 pathogenic variants (Hu et al. 2021). This evidence concerns the gene TP53 and cancer.